Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Haisco Pharmaceutical Group Co: Clinical Trials & FDA Approval Profile

Haisco Pharmaceutical Group Co (Global / Institutional) sponsors 66 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 30 active protocols (13 recruiting now), 32 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)171 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Haisco Pharmaceutical Group Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)66
Active Pipeline (Recruiting Now)30 (13)
Completed vs Stopped Early32 / 0 (0.0%)
Median Closed Actual Enrollment171 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Haisco Pharmaceutical Group Co
Hospital Research SiteLocationShared Protocols
Peking University First HospitalBeijing, Beijing Municipality6
West China Hospital of Sichuan UniversityChengdu, Sichuan4
Xiangya Hospital of Central South UniversityChangsha, Hunan3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Haisco Pharmaceutical Group Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANPhase IIIRECRUITING
NCT07442877A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic SurgeryPhase IICOMPLETED
NCT05890053To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral NeuralgiaPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Haisco Pharmaceutical Group Co Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI